Amgen Inc. (AMGN)
| Market Cap | 154.74B |
| Revenue (ttm) | 32.53B |
| Net Income (ttm) | 4.23B |
| Shares Out | 537.53M |
| EPS (ttm) | 7.83 |
| PE Ratio | 36.75 |
| Forward PE | 13.96 |
| Dividend | $9.00 (3.13%) |
| Ex-Dividend Date | Nov 18, 2024 |
| Volume | 4,229,854 |
| Open | 281.10 |
| Previous Close | 279.95 |
| Day's Range | 278.62 - 288.48 |
| 52-Week Range | 260.68 - 346.85 |
| Beta | 0.60 |
| Analysts | Buy |
| Price Target | 334.58 (+16.23%) |
| Earnings Date | Oct 30, 2024 |
About AMGN
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company’s principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; N... [Read more]
Financial Performance
In 2023, Amgen's revenue was $28.19 billion, an increase of 7.09% compared to the previous year's $26.32 billion. Earnings were $6.72 billion, an increase of 2.52%.
Financial StatementsAnalyst Forecast
According to 22 analysts, the average rating for AMGN stock is "Buy." The 12-month stock price forecast is $334.58, which is an increase of 16.23% from the latest price.
News
AMGEN ANNOUNCES SENIOR EXECUTIVE RESEARCH APPOINTMENT
Howard Chang, M.D., Ph.D., Joins as Senior Vice President of Research and Chief Scientific Officer THOUSAND OAKS, Calif.
RFK Jr.'s HHS nomination sparks concern over pharma stocks
President-elect Trump's decision to nominate Robert F. Kennedy Jr. as the Secretary of Health and Human Services (HHS) has sparked concerns, particularly about his skepticism toward the pharmaceutical...
Amgen Sells Off: Keep Calm And Buy The Dip
Amgen's stock dropped nearly 15% last week due to safety concerns about its GLP-1 candidate MariTide. Amgen's management and analysts downplayed the bone mineral density concerns, emphasizing MariTide...
Stock Market Today: Stocks Drop as Post-Election Party Ends
It was a red finish on Wall Street Friday with tech stocks selling off ahead of Nvidia's upcoming earnings event.
RFK Jr. is not a fan of weight-loss drugs or vaccines. Stocks are tanking.
The stocks of companies that make or are developing the new class of weight-loss and diabetes-management drugs were sharply lower Friday, after President-elect Donald Trump named Robert F. Kennedy Jr....
AMGEN PRESENTS NEW DATA ACROSS RARE INFLAMMATORY DISEASES AT ACR 2024
MITIGATE Phase 3 Study Results Reinforce Promise of UPLIZNA® as the First Potential Treatment tor IgG4-RD Phase 4 AGILE Data Support Shortening KRYSTEXXA® Infusion Time THOUSAND OAKS, Calif. , Nov. 14...
5 Healthcare Stocks to Buy in a Beaten-Up Sector
It has been a shaky time for healthcare stocks, but that only presents a buying opportunity.
Amgen Inc. (AMGN) UBS Global Healthcare Conference (Transcript)
Amgen Inc. (NASDAQ:AMGN) UBS Global Healthcare Conference November 13, 2024 1:15 PM ET Company Participants Peter Griffith - CFO Narimon Honarpour - SVP, Global Development Justin Claeys - VP, IR Con...
Signal Says Pharma Stock Selloff Should Be Over
Shares of pharmaceutical giant Amgen (AMGN) are attempting to bounce back after suffering a steep drop of 7.1% yesterday, following reports that the company's weight-loss drug, MariTide, triggers a si...
Amgen Defends Its Investigational Monthly Weight Loss Injection After Analyst Cites MariTide's Impact on Bone Density
On Tuesday, a Cantor analyst wrote that additional data from Amgen's experimental weight loss injection, MariTide, suggests a new potential safety risk tied to the drug.
Trade Tracker: Joe Terranova sells Amgen and buys XBI
Joe Terranova, senior managing director for Virtus Investment Partners, joins CNBC's 'Halftime Report' to discuss his latest portfolio moves.
What's Happening With Amgen Stock?
Amgen stock (NASDAQ: AMGN) saw a 7% fall on Tuesday, November 12, after an update on the progress with its weight-loss drug — MariTide. An early-stage trial for the drug showed loss of bone density, w...
Amgen sees no bone safety concerns around experimental obesity drug
Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone mineral density, a day after data from an early-stage study dragged its stock 7% lower.
AMGEN PROVIDES STATEMENT ON MARITIDE PHASE 1 DATA
THOUSAND OAKS, Calif. , Nov. 13, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today issued the following statement on the MariTide (maridebart cafraglutide, formerly AMG 133) Phase 1 data.
Amgen sinks as Cantor flags issues with obesity drug
Olivia Brayer, Cantor Fitzgerald, joins 'Fast Money' to discuss Amgen shares sliding on bone density data.
Amgen stock falls as analysts mull over weight loss drug's bone density data
Shares of Amgen fell as analysts chewed over bone density loss data from an early-stage trial on its experimental weight loss injection, MariTide. While some analysts called the additional data a pote...
AMGEN TO PRESENT AT THE 2024 UBS GLOBAL HEALTHCARE CONFERENCE
THOUSAND OAKS, Calif. , Nov. 8, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 2024 UBS Global Healthcare Conference at 10:15 a.m.
TEZSPIRE MET BOTH CO-PRIMARY ENDPOINTS IN PHASE 3 TRIAL FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPS
Statistically Significant Reduction in Nasal Polyp Size, Nasal Congestion Compared to Placebo THOUSAND OAKS, Calif. , Nov. 7, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and AstraZeneca today announced p...
Amgen Inc. (AMGN) Q3 2024 Earnings Call Transcript
Amgen Inc. (NASDAQ:AMGN) Q3 2024 Earnings Conference Call October 30, 2024 4:30 PM ET Company Participants Justin Claeys - VP, IR Robert Bradway - Chairman, CEO & President Murdo Gordon - EVP, Global...
Amgen posts higher 3rd-quarter profit, sales rise 24%
Amgen reported higher quarterly earnings on Wednesday, driven by a 24% rise in sales of products including cholesterol drug Repatha and Prolia for osteoporosis, and said results of a mid-stage trial o...
AMGEN REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS
THOUSAND OAKS, Calif. , Oct. 30, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the third quarter of 2024.
AMGEN ANNOUNCES 2024 FOURTH QUARTER DIVIDEND
THOUSAND OAKS, Calif. , Oct. 25, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.25 per share dividend for the fourth quarter of 2024.
Amgen Q3 Earnings Review: So Many Questions, But MariTide Data Top Of The List
Amgen Inc.'s Q3 earnings — due 30th October -are unlikely to be a major upside catalyst due to tricky comparisons, increased R&D spending, and transitional phase challenges. Key patents expiring on se...
AMGEN ANNOUNCES WEBCAST OF 2024 THIRD QUARTER FINANCIAL RESULTS
THOUSAND OAKS, Calif. , Oct. 24, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its third quarter 2024 financial results on Wednesday, October 30, 2024, after the close o...